GET DAILY SIGNALSAardvark Therapeutics (AARD) Q3 2026 Earnings: Pipeline Updates and Cash Runway in Focus
Key Takeaways
- Aardvark Therapeutics (AARD) is set to release its third-quarter 2026 results on November 12, 2026, after the market close.
- Wall Street consensus points to a loss of about $0.72 per share, modestly better than the $0.75 loss from the same quarter last year.
- As a clinical-stage biotech with no product revenue, attention will center on R&D spending, cash burn rates, and the remaining cash runway.
- The main item to watch is any new information on the FDA clinical hold for ARD-101 and the outlook for the Prader-Willi Syndrome program.
- In Q2 2026, the company posted a smaller loss of $0.66 per share against expectations of roughly $0.87, thanks largely to lower R&D costs.
Why This Report Matters
Aardvark Therapeutics develops treatments for hyperphagia and related metabolic issues, with ARD-101 as its primary candidate. Without any commercial revenue, each quarterly update offers a snapshot of clinical advancement, spending control, and financial position. The past few quarters have been challenging after the company ended its Phase 3 HERO and open-label extension studies for ARD-101 due to an FDA clinical hold. That step cut R&D outlays but left investors waiting for unblinded data that could clarify the program's direction. With shares well below prior peaks, the upcoming release should help show whether the company can maintain value during this reset phase.
What the Numbers Are Expected to Show
Analysts are looking for a loss of approximately $0.72 per share in the third quarter of fiscal 2026, per consensus figures from TipRanks, compared with a $0.75 per-share loss a year earlier. Revenue is projected to stay at zero. In the prior quarter, Aardvark beat estimates with a $0.66 loss versus roughly $0.87 expected, helped by R&D expenses falling to about $10.5 million after the Phase 3 trials ended. G&A costs rose about 71% year over year from public-company expenses and severance. I will be watching whether R&D remains controlled, how G&A develops, and if management keeps its cash-runway guidance into late 2027 backed by roughly $73.9 million in liquidity. When screening peers in the space, I also checked this using Tickeron’s AI Screener to compare spending patterns across similar names.
Current Sentiment and Recent Price Action
Investor mood ahead of the report is measured. The stock has moved sharply since its 2025 listing and sits well below its 52-week highs after the clinical hold and trial halts. Past earnings have produced negative reactions, with shares dropping about 8.6% the day after the August 2026 release and around 5% following the May 2026 update. Main risks include the open FDA hold, questions over whether unblinded data will support further work on ARD-101 in PWS, and any need for additional capital or restructuring. For a pre-revenue company, updates on cash runway and strategy are likely to carry more weight than the headline loss number.
What Comes Next
The biggest near-term driver remains clarity on the FDA clinical hold for ARD-101 and the results of the unblinded data review that management has said will guide the PWS program's path. A workable route to restart or adjust development would likely be received better than any move to set the asset aside. Spending discipline comes next. With R&D already trimmed, the focus will be on whether costs hold steady and how quickly G&A normalizes as severance effects ease. The stated runway into late 2027 offers some buffer, yet any rise in burn or new trial plans could raise financing questions. Broader biotech market conditions and interest in early-stage metabolic and rare-disease assets will also shape how the quarter is viewed. From what I see, steady communication on program plans and prudent capital use will matter most to sentiment.
Refining Research with AI Tools
One resource I turn to when evaluating clinical-stage names like this is Tickeron’s AI-powered screening capabilities. It lets me quickly filter for comparable companies by fundamentals, volatility, and technical signals, which helps put Aardvark’s metrics in better context without spending hours on manual checks. The same platform has proven handy for spotting other opportunities in the sector when pipeline timelines shift.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AARD in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 23, 2026
AARD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 7 of 8 cases where AARD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AARD's RSI Oscillator exited the oversold zone, 7 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 13 of 17 cases where AARD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on AARD as a result. In 21 of 25 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for AARD just turned positive on November 10, 2026. Looking at past instances where AARD's MACD turned positive, the stock continued to rise in 14 of 17 cases over the following month. The odds of a continued upward trend are 82%.
Following a +17.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where AARD advanced for three days, in 88 of 102 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AARD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AARD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.342) is normal, around the industry mean (3.498). P/E Ratio (-0.363) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. AARD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AARD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement